Oncotrace: Assess cancer progression

Monitor tumor growth for optimized treatment strategies

Our Oncotrace test is a powerful monitoring tool designed to evaluate cancer progression and support tumor staging. Through a simple blood draw, Oncotrace detects and analyzes circulating tumor cells (CTCs), evaluating their presence, enumeration, and immunophenotype using flow cytometry. This information helps determine how advanced the cancer is and the potential for metastatic spread. This cancer blood test also supports in underlining the primary origin of the tumor.

By tracking CTC dynamics over time, the cancer blood test Oncotrace enables physicians to monitor key tumor markers associated with migration, proliferation, resistance, and metastasis. This comprehensive analysis allows clinicians to more accurately assess disease progression, evaluate treatment effectiveness, and make informed therapeutic decisions.

How does the Oncotrace test work?

Through a blood sample, Oncotrace from RGCC establishes baseline values for circulating tumor cell (CTC) count, phenotype markers, and stemness markers in the bloodstream. Together, these parameters provide a detailed picture of cancer activity and treatment response. 

• Circulation Tumor Cell Count: Measures the number of cancer cells circulating in the bloodstream. Tracking changes in this count helps physicians assess treatment effectiveness, disease progression, and make timely, personalized clinical decisions. 

• Phenotype markers: The immunophenotype helps identify the tissue from which the tumor originates. 
  It also reveals important information about the characteristics of the cancer, such as the likelihood of metastasis, disease progression, and potential resistance to therapies. 
• Stemness markers: Indicate the activity and regenerative potential of cancer stem cells. The presence of active stemness markers suggests the need to continue treatment, even when CTC counts appear low, ensuring that residual disease is not overlooked.